Salvage HDR brachytherapy for prostate cancer: a high-volume center experience on 100 consecutive patients

Figures & data

Table 1. Characteristics of patients treated with salvage HDR brachytherapy in Helsinki University Hospital between February 2015 and April 2020.

Patient characteristics (n = 100)
Median age (range)	72 (58–80)
Primary Gleason score
6	51
7	39
8	5
9	5
Relapse Gleason score
6	8
7	37
8	19
9	33
10	2
NA	1
PSA before salvage-HDR (ng/ml) median (range)	1.93 (0–30.4)
Primary treatment
EBRT	82
LDR	18
Time between primary treatment and salvage-HDR, median (range)	10 years (1–19)
<5 Years	8
5–9 Years	36
>10 Years	56
ADT during salvage-HDR
Combined androgen blockade	15
LHRH	42
Bicalutamide	12
No ADT	31
MRI before salvage-HDR
Positive	91
Negative	7
Not assessed	2
Imaging modality for staging
Gallium68-PSMA-PET/CT	88
Choline-PET/CT	8
None	4

Table 2. Acute and late toxicity in patients treated with salvage HDR brachytherapy in Helsinki University Hospital between February 2015 and April 2020.

	Acute toxicity n = 100	Late toxicity n = 55
Genitourinary
None	30	0
Grade 1	58	12 (22%)
Grade 2	12	0
Gastrointestinal
none	92	0
Grade 1	8	4 (7%)
Grade 2	0	0

Figure 1. (a) Overall survival after salvage HDR brachytherapy. (b) Overall survival after salvage HDR brachytherapy according to presalvage Gleason score.

Figure 2. Biochemical recurrence-free survival after salvage HDR brachytherapy according to presalvage Gleason score.